Results 61 to 70 of about 22,830 (227)
Optimization of B Cell Responses in Human Immune System Mice Through Organoid Based Screening
Advanced Science, EarlyView.Human immune system (HIS) mice show limited B cell responses to immunization. Using HIS mouse spleen organoids, this study identifies cytokine combinations and innate immune signals that drive human B cell expansion, differentiation, and class‐switch. Applying these signals in vivo through temporal separation enables antigen‐specific IgG responses and ...
Haiqiao Sun +6 more
wiley +1 more source
Abstract 1523: The mechanism of action of BCL6 in glioblastoma [PDF]
, 2017 Glioblastoma (GBM) is the most common and most deadly brain tumor to occur in adults. Initially patients respond to radiation and chemotherapy, which primarily work by causing large amounts of DNA damage, causing apoptosis of the cells.
Dinindu Sachindra Senanayake +5 more
core +1 more source
Advanced Science, EarlyView.ABHD17C‐mediated depalmitoylation of BCL6B at Cys442 blocks its nuclear import and triggers ubiquitin‐dependent degradation, attenuating transcriptional repression of the anti‐phagocytic signal CD24. This mechanism enables pancreatic cancer cells to evade macrophage phagocytosis and fosters an immunosuppressive microenvironment.
Yalu Zhang +9 more
wiley +1 more source
Structural basis of Apt48 inhibition of the BCL6 BTB domain [PDF]
, 2022 B cell lymphoma 6 (BCL6) is a transcriptional repressor that is deregulated in diffuse large B cell lymphoma, and the peptide aptamer, Apt48, inhibits BCL6 by an unknown mechanism. We report the crystal structure of BCL6 in complex with an Apt48 peptide,
Wright, SC +5 more
core +1 more source
Advanced Science, EarlyView.S100A8/A9‐high macrophages are markedly enriched in the stenotic intestinal tissue of patients with Crohn's disease. These profibrotic macrophages secrete mCCL6 in a STAT3‐dependent manner. mCCL6 and its human ortholog hCCL15 activate fibroblasts via the CCR1 receptor, thereby driving excessive collagen deposition.
Shu Wang +12 more
wiley +1 more source
Abstract 2166: Arsenic trioxide targets BCL6 oncoprotein for degradation in BCL6-dependent diffuse large B-cell lymphoma [PDF]
, 2017 Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma throughout the world. B-cell lymphoma 6 (BCL6) overexpression is frequently observed in DLBCL.
Lok Man Yue +4 more
core +1 more source
The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress
eLife, 2022 Genotoxic agents remain the mainstay of cancer treatment. Unfortunately, the clinical benefits are often countered by a rapid tumor adaptive response. Here, we report that the oncoprotein B cell lymphoma 6 (BCL6) is a core component that confers solid ...
Yanan Liu +10 more
doaj +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez +17 more
wiley +1 more source
Animal Models and Experimental Medicine, EarlyView.At the genomic level, a large number of differentially expressed genes (DEGs) and aging‐related DEGs have been screened. Ten hub genes, such as IFNγ and IRF7, have been identified and shown potential value in the diagnosis of PD, holding promise as novel biomarkers to facilitate early and precise diagnosis.
Haojie Wu +3 more
wiley +1 more source
Purification of antibody against BCL6. [PDF]
, 2019 (A) SDS-PAGE analysis of antibodies against BCL6 after purification. M: Marker (Blue plus II protein marker); lane 1: protein profile of ascites fluid; lane 2: the purified mAb against BCL6 (1E6A4).
Kunzhi Jia (323418) +8 more
core +1 more source